UNSPSC 51171644: Sulisatin

This classification denotes a laxative with the molecular formula C21H17NO9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5EOG8KQT0Y, chemically known as 3,3-bis(4-hydroxyphenyl)-7-methyl-2-indolinone, disodium salt of sulfuric acid diester but generally known as sulisatin, which bears US NIH Compound Identifier 41237. European Medicines Agency schedules Sulisatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10745MIG.

UNSPSC 51171644 Sulisatin, a Commodity code, covers pharmaceutical active ingredients and chemical compounds used in drug formulation and synthesis, but state and local government solicitations tagged with this code predominantly address specimen collection, drug testing services, and pharmaceutical distribution rather than raw sulisatin procurement. The work being solicited reflects therapeutic pharmacy programs, offender drug screening operations, and multistate cooperative purchasing of finished pharmaceuticals and over-the-counter products — categories that diverge substantially from the code's nominal scope of chemical compounds. Issuing bodies include county community supervision departments, state health and human services agencies, and multistate cooperative purchasing alliances. The mix suggests the code may be misapplied across disparate procurement domains rather than reflecting consistent purchasing of sulisatin as a manufactured ingredient.

Recent opportunities span Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with optional renewals, requiring vendor staffing at two collection sites, laboratory certification from SAMHSA or CAP, and multi-panel immunoassay screening with confirmation testing for approximately 25,031 annual tests. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with proposals due March 26, 2026, contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The code shows limited recent relevant activity aligned with its sulisatin definition.